Long-Acting Nanomedicine for Tuberculosis: A Mechanism-Informed Framework
- 1Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia
Abstract
Tuberculosis treatment remains prolonged because effective therapy must maintain coordinated multidrug exposure across heterogeneous lesions, bacterial states, and intracellular compartments. Long-acting nanomedicine may reduce adherence-related vulnerability and improve drug delivery, but prolonged release alone do not ensure lesion sterilization or treatment shortening. This review presents a mechanism-informed framework linking lesion architecture, local microenvironment, bacterial phenotypic adaptation, intracellular survival, and immunopathological organization to specific formulation functions. These include sustained active exposure, pulmonary and intralesional delivery, intracellular drug release, multidrug synchronization, and controlled host-directed therapy. Injectable depots, inhalable systems, cellular targeting, and polymeric platforms, including PLGA, other polyesters, hydrogels, natural polymers, and hybrid systems, is evaluated according to biological relevance, spatial delivery, pharmacodynamic activity, and translational feasibility. The most realistic near-term application is the development of simple, manufacturable long-acting formulations of established antimycobacterial drugs to improve exposure continuity and treatment completion. Treatment shortening will require synchronized sterilizing exposure across relevant compartments and evidence of relapse prevention.
Related
- Mechanism-informed machine learning for interpretable drug release prediction and virtual formulation intervention in polymeric long-acting injectables
- Diagnosing recurring explanatory gaps and proposing a mechanism-based psychoeducational framework in Islamic-tradition long-term care: a model informed by the moral exemplarity of the prophet Muhammad
- From past to present and toward the future: a mechanism-informed clinical framework for COVID-19-associated headache and post-viral pain
- Determinants of variable response to GLP-1 receptor agonists: A mechanism-informed framework for precision treatment of obesity.
- Mechanism-Driven Nanomedicine for Radiation Injury and Protection: Redox Homeostasis, the DNA Damage Response, and Microbiome-Based Strategies.
BibTeX
@article{herdiana2026longacting,
title = {{Long-Acting Nanomedicine for Tuberculosis: A Mechanism-Informed Framework}},
author = {Yedi Herdiana},
journal = {International Journal of Nanomedicine},
year = {2026},
month = nov,
doi = {10.2147/ijn.s641702},
url = {https://doi.org/10.2147/ijn.s641702},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Long-Acting Nanomedicine for Tuberculosis: A Mechanism-Informed Framework
AU - Yedi Herdiana
PY - 2026
DA - 2026/11/01
JO - International Journal of Nanomedicine
DO - 10.2147/ijn.s641702
UR - https://doi.org/10.2147/ijn.s641702
AB - Tuberculosis treatment remains prolonged because effective therapy must maintain coordinated multidrug exposure across heterogeneous lesions, bacterial states, and intracellular compartments. Long-acting nanomedicine may reduce adherence-related vulnerability and improve drug delivery, but prolonged release alone do not ensure lesion sterilization or treatment shortening. This review presents a mechanism-informed framework linking lesion architecture, local microenvironment, bacterial phenotypic adaptation, intracellular survival, and immunopathological organization to specific formulation functions. These include sustained active exposure, pulmonary and intralesional delivery, intracellular drug release, multidrug synchronization, and controlled host-directed therapy. Injectable depots, inhalable systems, cellular targeting, and polymeric platforms, including PLGA, other polyesters, hydrogels, natural polymers, and hybrid systems, is evaluated according to biological relevance, spatial delivery, pharmacodynamic activity, and translational feasibility. The most realistic near-term application is the development of simple, manufacturable long-acting formulations of established antimycobacterial drugs to improve exposure continuity and treatment completion. Treatment shortening will require synchronized sterilizing exposure across relevant compartments and evidence of relapse prevention.
SN - 1176-9114
SN - 1178-2013
ER -